welcomes you to the new, improved website!This phase II trial evaluated outcomes of isolated lung perfusion with Melphalan and complete surgical resection for pulmonary metastases from colorectal cancer or sarcoma in 50 pts. Surgical mortality was 0%, but morbidity (primarily grade 3 or 4 pulmonary morbidity) was 44%. 30 patients suffered local recurrence. 3-year survival was 57% and recurrence-free survival was 36%.
You are here:
Phase II Multicenter Clinical Trial of Pulmonary Metastasectomy and Isolated Lung Perfusion with Melphalan in Patients with Resectable Lung Metastases
Submitted by: Mark Ferguson
Source: Journal of Thoracic Oncology
Keywords:
Author(s): den Hengst, Willem A.; Hendriks, Jeroen M.H.; Balduyck, Bram; Rodrigus, Inez; Vermorken, Jan B.; Lardon, Filip; Versteegh, Michel I.M.; Braun, Jerry; Gelderblom, Hans; Schramel, Franz M.N.H.; Van Boven, Wim-Jan; Van Putte, Bart P.; Birim, Özcan; Maat, Alexander P.W.M.; Van Schil, Paul E.Y.
